Veru Inc (VERU) Stock AnalysisVERUVeru Inc

Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Veru Inc. (VERU) is a good buy right now due to its recent clinical trial progress and a strong cash position of $23.9 million, which supports future R&D. The current price is $2.625, significantly below the analyst price target of $25, indicating substantial upside potential. However, the company has reported a negative EPS of -0.30 for Q3 2026, which is a risk to consider.

1 analysts cover VERU: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 25.00.